Evidence map›Paper›PMID 31965747›Full record

ArticleJournal of cachexia, sarcopenia and muscle2020

Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction.

Thomas Kunzke, Achim Buck, Verena M Prade, Annette Feuchtinger, Olga Prokopchuk, Marc E Martignoni, Simone Heisz, Hans Hauner, Klaus-Peter Janssen, Axel Walch and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Risk Factors of Sarcopenia in COPD Patients: A Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2024
    Pooled it
  2. Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Immunoregulation in cancer-associated cachexia.Journal of advanced research · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Thomas KunzkeResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.
Achim BuckResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.
Verena M PradeResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.
Annette FeuchtingerResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.
Olga ProkopchukDepartment of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.
Marc E MartignoniDepartment of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.
Simone HeiszElse Kroener-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, TUM, Munich, Germany.
Hans HaunerElse Kroener-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, TUM, Munich, Germany.
Klaus-Peter JanssenDepartment of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.
Axel WalchResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.ORCID 0000-0001-5578-4023
Michaela AichlerResearch Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.
Helmholtz Zentrum München · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCachexia is the direct cause of at least 20% of cancer-associated deaths. Muscle wasting in skeletal muscle results in weakness, immobility, and death secondary to impaired respiratory muscle function. Muscle proteins are massively degraded in cachexia; nevertheless, the molecular mechanisms related to this process are poorly understood. Previous studies have reported conflicting results regarding the amino acid abundances in cachectic skeletal muscle tissues. There is a clear need to identify the molecular processes of muscle metabolism in the context of cachexia, especially how different types of molecules are involved in the muscle wasting process.

methodsNew in situ -omics techniques were used to produce a more comprehensive picture of amino acid metabolism in cachectic muscles by determining the quantities of amino acids, proteins, and cellular metabolites. Using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging, we determined the in situ concentrations of amino acids and proteins, as well as energy and other cellular metabolites, in skeletal muscle tissues from genetic mouse cancer models (n = 21) and from patients with cancer (n = 6). Combined results from three individual MALDI mass spectrometry imaging methods were obtained and interpreted. Immunohistochemistry staining for mitochondrial proteins and myosin heavy chain expression, digital image analysis, and transmission electron microscopy complemented the MALDI mass spectrometry imaging results.

resultsMetabolic derangements in cachectic mouse muscle tissues were detected, with significantly increased quantities of lysine, arginine, proline, and tyrosine (P = 0.0037, P = 0.0048, P = 0.0430, and P = 0.0357, respectively) and significantly reduced quantities of glutamate and aspartate (P = 0.0008 and P = 0.0124). Human skeletal muscle tissues revealed similar tendencies. A majority of altered amino acids were released by the breakdown of proteins involved in oxidative phosphorylation. Decreased energy charge was observed in cachectic muscle tissues (P = 0.0101), which was related to the breakdown of specific proteins. Additionally, expression of the cationic amino acid transporter CAT1 was significantly decreased in the mitochondria of cachectic mouse muscles (P = 0.0133); this decrease may play an important role in the alterations of cationic amino acid metabolism and decreased quantity of glutamate observed in cachexia.

conclusionsOur results suggest that mitochondrial dysfunction has a substantial influence on amino acid metabolism in cachectic skeletal muscles, which appears to be triggered by diminished CAT1 expression, as well as the degradation of mitochondrial proteins. These findings provide new insights into the pathobiochemistry of muscle wasting.

Indexed as

Amino AcidsCachexiaFemaleHumansInfantMaleMitochondrial ProteinsMuscle, SkeletalAmino AcidsMitochondrial ProteinsAmino acidsCancer cachexiaMALDIMass spectrometry imagingMitochondrial dysfunctions

Identifiers

PMID31965747
PMCPMC7015243
OpenAlexW2985238969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.